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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.006Myeloperoxidase (MPO) is a target antigen for antineutrophil cytoplasmic autoantibodies (ANCA). There
is evidence that MPO-ANCA cause necrotizing and crescentic glomerulonephritis (NCGN) and vasculitis.
NCGN severity varies among patients with ANCA disease, and genetic factors inﬂuence disease severity.
The role of genetics in MPO-ANCA NCGN severity was investigated using 13 inbred mouse strains, F1 and
F2 hybrids, bone marrow chimeras, and neutrophil function assays. Mouse strains include founders of
the Collaborative Cross. Intravenous injection of anti-MPO IgG induced glomerular crescents in >60% of
glomeruli in 129S6/SvEv and CAST/EiJ mice, but <1% in A/J, DBA/1J, DBA/2J, NOD/LtJ, and PWK/PhJ
mice. C57BL6J, 129S1/SvImJ, LP/J, WSB/EiJ, NZO/HILtJ, and C3H mice had intermediate severity.
High-density genotypes at 542,190 single nucleotide polymorphisms were used to identify candidate
loci for disease severity by identifying genomic regions that are different between 129S6/SvEv and
129S1/SvImJ mice, which are genetically similar but phenotypically distinct. C57BL/6  129S6 F2 mice
were genotyped at 76 SNPs to capture quantitative trait loci for disease severity. The absence of
a dominant quantitative trait locus suggests that differences in severity are the result of multiple gene
interactions. In vivo studies using bone marrow chimeric mice and in vitro studies of neutrophil
activation by anti-MPO IgG indicated that severity of NCGN is mediated by genetically determined
differences in the function of neutrophils. (Am J Pathol 2013, 182: 1219e1226; http://dx.doi.org/
10.1016/j.ajpath.2012.12.006)Supported by NIH NIDDK grant 2-P01-DK058335-11 (H.X., P.H.,
R.J.F., and J.C.J.).
H.X. and D.C. contributed equally to this work.
Portions of these data were presented at the annual meeting of the United
States and Canadian Academy of Pathology, March 20e26, 2010, Wash-
ington, DC, as Abstract 1549.Anti-neutrophil cytoplasmic autoantibodies (ANCA), in-
cluding ANCA speciﬁc for myeloperoxidase (MPO-ANCA),
are associated with systemic vasculitis and pauci-immune
necrotizing crescentic glomerulonephritis (NCGN), and there is
strong evidence that MPO-ANCA are pathogenic.1 NCGN is
induced in mice by injecting anti-MPO IgG,2e5 and is
mediated by neutrophils, enhanced by neutrophil priming,
modulated by Fc gamma receptor engagement, and requires
alternative complement pathway activation.2e7
Patients with ANCA disease have varied NCGN severity,
ranging from 100% to <5% crescents (average, 50%),8 and
a minority of patients have systemic small vessel vasculitis
with noglomerulonephritis.1 Evidence for genetic inﬂuenceon
ANCA-associated disease includes familial occurrences,9e13
greater frequency in ﬁrst-degree relatives,14 differences in
racial incidence,14e17 association betweendisease severity and
polymorphisms in genes that inﬂuence immune responses and
inﬂammation,18e28 and a genome-wide association study thatstigative Pathology.
.indicates genetically determined differences between disease
associated with MPO-ANCA versus proteinase 3especiﬁc
ANCA (PR3-ANCA).29
Intravenous injection of anti-MPO IgG into C57BL/6
(B6) mice induces NCGN with crescent formation in
approximately 5% to 10% of glomeruli in 100% of mice.2e7
To investigate the effect of genetic backgrounds on disease
severity, anti-MPO IgG was injected into 12 additional
mouse strains, which demonstrated substantial differences in
disease susceptibility and severity. High-density genotyping
was used to identify candidate loci for disease severity by
identifying genomic regions that are different between
Xiao et algenetically similar, but phenotypically distinct, sister strains.
F2 mice from a cross between low-severity B6 mice and
high-severity 129S6/SvEv (129S6) mice were genotyped to
identify quantitative trait loci (QTL) for disease severity.
In vivo studies using bone marrow (BM) chimeric mice and
in vitro studies of neutrophil activation by anti-MPO IgG
demonstrated that NCGN severity is mediated by geneti-
cally determined differences in neutrophil function.
Materials and Methods
Mice
C57B6/6J (B6), 129S6/SvEv (129S6), 129S1/SvImJ (129S1),
LP/J (LP), WSB/EiJ (WSB), NZO/H1LtJ (NZO), PWK/PhJ
(PWK), NOD/LtJ (NOD), DBA1, DBA2, AJ, C3H, and
CAST/Ei (CAST), C57BL/6J (B6) and LP/J (LP) mice were
purchased from Jackson Laboratories (Bar Harbor, ME).
129S6/SvEv (129S6), 129S1, Rag2 knockout with B6.SJL
background (Rag2/B6), and Rag2 knockout with 129S6/
SvEv background (Rag2/129S6) mice were purchased
from Taconic Farms (Germantown, NY). NOD/LtJ, NZO/
H1LtJ, PWK/PhJ, and WSB/EiJ were obtained from the
University of North Carolina Department of Genetics. MPO
knockout (Mpo/) mice were initially generated by Aratani
and colleagues.30 B6, 129S1, NOD, NZO, PWK, WSB,
CAST, and A/J strains are founders of the Collaborative
Cross31,32 and capture 90% of the genetic diversity among
laboratorymice. F1micewere generated byB6 backcrosswith
129S6 mice, and 100 F2 mice were generated by (B6X129S6)
F1 intercross. Mice were maintained by University of North
Carolina Division of Laboratory Animal Medicine in adher-
ence to the 2011 NIH Guide for Care and Use of Laboratory
Animals.
Preparation of Pathogenic Mouse Anti-Murine MPO IgG
Puriﬁcation of native mouse MPO and immunization of
Mpo/micewere performed as described.2Mpo/mice 8 to
10 weeks old were immunized intraperitoneally with 20 mg of
puriﬁed murine MPO in complete Freund’s adjuvant and
boosted twice with 10 mg of MPO in incomplete Freund’s
adjuvant. Anti-MPO was monitored by enzyme-linked immu-
nosorbent assay. Anti-MPO IgG was isolated from serum of
Mpo/ mice immunized with MPO by 50% ammonium
sulfate precipitation and protein G afﬁnity chromatography.2
Purity of antibodies was conﬁrmed by SDS-PAGE electro-
phoresis, and protein concentrations determined by Coomassie
protein assay (Pierce, Rockford, IL).
Induction of Glomerulonephritis with Anti-MPO IgG
Mice were injected intravenously with 50 mg/g bodyweight
mouse anti-mouse MPO IgG.2 After 6 days, mice were
sacriﬁced and kidneys examined by light microscopy for
NCGN. For BM transplantation experiments, 6 weeks after1220BM transfer, Rag2/ mice were injected intravenously
with 50 mg/g body weight of anti-MPO IgG and sacriﬁced
6 days later.
Pathological Evaluation
Kidneys were collected at the time of sacriﬁce and ﬁxed in
10% formalin, embedded in parafﬁn, sectioned at 4 mm,
stained with H&E and periodic acid Schiff, and then eval-
uated by light microscopy. The extent of glomerular cres-
cents and necrosis were expressed as mean % glomeruli
with crescents or necrosis by counting all glomeruli in cross
sections of both kidneys, which averaged approximately
80 per mouse. Glomerular leukocytes in kidneys from BM
chimeric mice were evaluated by immunohistochemistry on
parafﬁn sections.
BM Chimeras
BM cells were harvested from femurs and tibia of B6 and
129S6 mice, and erythrocytes removed by hypotonic lysis.7
Age-matched Rag2/B6 and Rag2/129S6 recipient
mice were kept under sterile conditions and given acidiﬁed
water with 0.2% neomycin at least 1 week before irradiation.
Recipients were lethally g-irradiated with 900 rad, and 12 to
24 hours later were reconstituted intravenouslywith 1.5 107
donor BM cells: 129/S6 donor cells into Rag2/B6 recipi-
ents (129S6/ Rag2/B6 chimeras), B6 donor cells into
Rag2/129S6 recipients (B6/ Rag2/129S6 chimeras).
Successful transplantation was conﬁrmed by ﬂow cytometry
measuring CD45.1 and CD45.2 (BD Pharmingen, San Jose,
CA), which distinguish leukocytes from recipients and
donors.
In Vitro Neutrophil Activation by Anti-MPO IgG
Superoxide dismutase (SOD)-inhibitable reduction of ferri-
cytochrome C was used to measure neutrophil oxidative
activity. Neutrophils were suspended at 1  107 in HBSS
buffer and pretreated with 5 mg/mL cytochalasin B for 15
minutes at 4C. Neutrophils (5  105, in HBSS) were
prewarmed with 50 mmol/L ferricytochrome with or without
300 U/mL SOD for 15 minutes at 37C and then primed
with 2 ng/mL tumor necrosis factor-alpha (TNF-a) for 15
minutes at 37C. Primed neutrophils were incubated with
250 mg/mL anti-mouse MPO IgG at 37C, and absorption of
samples was scanned at 550 nm every 5 minutes for 60
minutes using a Microplate Autoreader (Molecular Devices,
Sunnyvale, CA).
Comparative Genomic Evaluation
Genetic variation among mouse strains was determined by
comparing publically available high-density genotypes at
542,190 single nucleotide polymorphisms (SNPs) using
a mouse diversity array.33e36 Genomic clustering ofajp.amjpathol.org - The American Journal of Pathology
Table 1 Anti-MPO IgGeInduced Glomerular Lesions in Different
Strains of Mice
Mouse Mice with
Mean %
crescents
when Mice with
Mean %
necrosis
when
Anti-MPO Glomerulonephritisidentical genotypes was performed to identify regions
identical by descent (IBD). IBD was performed by counting
the number of identical SNPs in 100 SNP windows.
Windows with 98% genotype similarity were declared
IBD.36Strains numbers, n crescents, n present necrosis, n present
B6 27 27 9.5 27 4.0
129S6 24 24 63.7* 24 22.4*
129S1 22 22 21.1y 21 7.3y
LP 8 8 19.8 8 5.9
WSB 4 4 9.0 4 2.8
NZO 4 4 2.8 4 2.8
PWK 5 1 0.7 0 NA
NOD 4 0 NA 0 NA
DBA1 5 2 0.9 0 NA
DBA2 5 0 NA 0 NA
AJ 4 0 NA 0 NA
C3H 5 5 5.2 4 2.3
CAST 5 5 61.2 5 35.6
*P < 0.001 versus B6 and 129S1 mice.
yP > 0.4 versus LP mice.
NA, not applicable; no crescents or necrosis was observed.QTL Mapping
B6  129S6 F2 intercross was used to associate genetic
variants with NCGN phenotypes. Genomic DNA was iso-
lated from tails with a proteinase K/SDS lysis solution
followed by phenol-chloroform extraction. Ninety-nine
female F2 mice were genotyped at 76 SNPs using Seque-
nom iPEX MassARRAY (Sequenom, San Diego, CA) (1
of 108 samples was inadequate). The genetic map was
estimated using the R/qtl est.map function (R software;
http://www.r-project.org/)37,38 assuming genotyping error
of 0.001. Single-QTL interval mapping (IM) was performed
using the R/qtl scanone function on % crescents and log %
crescents. Log % crescents was distributed normally and IM
was performed using a normal model. % crescents was
mapped with a nonparametric IM model. A two-QTL model
was used for log % crescents using the R/qtl scantwo
function. Thresholds for both single- and two-QTL models
were determined by 1000 permutations.39Statistical Analysis
Tukey’s multiple comparison test was used for evaluating
differences in mean percent crescents between groups.Results
Survey of Mouse Strains Demonstrates Genetic Basis of
Severity of Anti-MPO NCGN
Mean % crescents induced by anti-MPO varied from 0% to
>60% in 13 mouse strains including 8 Collaborative Cross
founders that include 90% of the genetic diversity among
laboratory mice31,32 (Table 1 and Figures 1 and 2). 129S6/
SvEv (129S6) mice had 47 to 90% (mean 63.7%) compared
to 4 to 23% in B6 (mean 9.5%) (P < 0.001). 129S1 mice
developed an average of 21% crescents, which was a
signiﬁcant reduction (P < 0.001) compared to 129S6. LP/J
mice were included because they share ancestry with 129
mice33 and were found to have severity similar to 129S1
rather than 129S6. DBA1, DBA2, and C3H were included
because they have susceptibility to vasculitis in other
models. As shown in Figure 2 and Table 1, anti-MPO IgG
induced NCGN in WSB and C3H mice, similar to B6 mice.
CAST mice developed severe NCGN similar to 129S6.
NZO mice developed <5% crescents. Only a minority of
PWK and DBA1 mice developed crescents, affecting <1%
of glomeruli. NOD, AJ, and DBA2 mice were resistant to
NCGN induction.The American Journal of Pathology - ajp.amjpathol.orgComparative Genome Analysis of 129S6, 129S1, B6,
and LP Strains
129S6 and 129S1 have a signiﬁcantly different fraction of
glomeruli affected but are closely related, with most genetic
differences clustered.34,35 High-density genotypes were
compared between 129S6 and 129S1 strains (Table 2 and 3).
B6 and LP strains were also evaluated. The mouse diversity
array36,40 used for genotyping contains 542,190 SNPs. Of
these, 137,378 SNPs (25.34%) segregated among the four
strains. B6 differs from the other three strains at over 20% of
SNPs, LP differs from 129 at 7% to 8%, and the 129 sub-
strains differ from each other at <1% (Table 3).
We determined that the B6 strain is IBD with each of the
other three strains over 28% of the genome. The remaining
72% is a likely location of alleles associated with reduced
severity of NCGN. However, the IBD regions cannot be
eliminated as candidate regions that inﬂuence NCGN
phenotypes because genes within an IBD region could
interact with genes in non-IBD regions to inﬂuence disease.
More recent separation of the LP strain from the 129 sub-
strains resulted in a greater IBD fraction than for B6 (72% to
74%). The high degree of genetic similarity between 129S1
and 129S6 (>99% SNP matches) contrasted with striking
differences in NCGN severity. 129S1 and 129S6 are IBD at
96.7% of the genome (Table 2 and 3). The 3.3% non-IBD
fraction is conﬁned to 15 regions over 90.8 Mb on nine
chromosomes (Figure 3). These non-IBD regions contain
90% of mismatches between 129S1 and 129S6 (Table 2). In
these regions, the 129 substrains are as different from each
other as 129S6 is from B6 or LP, and 129S1 is from B6
(Table 3). 129S1 is IBD to LP across 8 of 15 regions (1, 2,
3, 5, 6, 11, 12, and 15; 56.0 Mb). Shared alleles in these
regions probably explain the similar phenotypes. 129S1 is1221
Figure 2 Severity of NCGN in 13 strains of mice and in B6  129S6 F1
and F2 mice, represented as the % of glomeruli with crescents. The two
groups of B6 mice received different antibody preparations.
Table 2 SNP Genotypes in IBD and Non-IBD Regions between
129S1 and 129S6
IBD Non-IDB
Total mismatches 460 4048
Fraction of mismatches 10.20% 89.80%
Fraction of genome 96.69% 3.31%
Frequency of mismatches 0.09% 22.85%
Figure 1 Photomicrographs demonstrating less severe NCGN caused by
anti-MPO IgG in a B6 mouse, with an arrow showing one of three glomeruli
with a crescent, compared to a 129S6 mouse, with arrows pointing to
crescents in four of four glomeruli and a background of secondary tubu-
lointerstitial changes (H&E stains).
Xiao et alIBD to B6 in region 10 (1.0 Mb) and is nearly identical in
regions 6 (11.7 Mb) and 1a (3.3 Mb). By contrast, 129S6 is
identical to B6 and LP only in regions 14 (1.2 Mb) and 4
(2.9 Mb) and is completely divergent across other regions.
These 15 regions (Figure 3), which contain 761 known
genes (Supplemental Table S1), are candidates for loci
mediating differences in NCGN between 129 substrains.
Linkage Analysis of C57BL/6  129S6 F2 Intercross
Female F1 mice produced by crossing B6 and 129S6 mice,
and female F2 mice produced by intercrossing F1 mice, were
injected with anti-MPO IgG. F1 mice (nZ 9) developed an
average of 13.6% crescents, and F2 mice (n Z 100)
developed a wide range of NCGN severity with clustering at
lesser severity, more like B6 than 129S6 (Figure 2).
The F2 intercross population was genotyped at 76 SNPs
to capture quantitative trait loci (QTL) for disease severity.
Suggestive QTL peaks were observed for log-transformed
% crescents on Chromosomes 4, 5, 7, 9, and 10; however,
no QTL peaks reached sufﬁcient genome-wide signiﬁcance,1222as calculated for 5% and 10% error thresholds. Suggestive
QTL on Chromosome 4 and Chromosome 9 do not include
129S6-129S1 non-IBD regions, thus these regions may
contain alleles that explain differences between B6 and
129S6. The suggestive QTL on Chromosome 5, 7, and 10
each span regions that have signiﬁcant divergence between
129 substrains. Based on this linkage analysis, differences in
disease severity are likely to result from multiple gene
interactions, and may involve epistasis.
BMeDerived Cells Mediate Genetic Differences in
Severity between Strains
To determine whether differences in NCGN severity
between B6 and 129S6 resulted from differences in function
of BM-derived cells, BM chimeric mice were produced.
Rag2/ B6 or Rag2/ 129S6 mice were lethally irradiated
followed by intravenous injection of 129S6 or B6 BM,
respectively, resulting in chimeras that had B6 bodies with
129S6 BM, or 129S6 bodies with B6 BM. Engraftment of
hematopoietic cells was conﬁrmed by ﬂow cytometric
measurement of % recipient common leukocyte antigen
(CD45.1 or CD45.2) positive peripheral blood leukocytesajp.amjpathol.org - The American Journal of Pathology
Table 3 Comparative Genotype Analysis Using the Mouse Diversity Array
129S6 vs B6 129S6 vs 129 S1 129S6 vs LP/J 129S1 vs LP/J 129S1 vs B6 B6 vs LP/J
Genome wide
Number of mismatches 115,069 4508 41,949 38,908 114,567 116,926
Percentage of mismatches 21.22% 0.83% 7.74% 7.18% 21.13% 21.57%
Percentage of matches 78.78% 99.17% 92.26% 92.82% 78.87% 78.43%
Percentage of IBD* 27.42% 96.69% 72.16% 74.43% 28.04% 27.99%
129S6 and 129S1 non-IBDy
Number of mismatches 4075 4048 3931 1100 3641 3481
Percentage of mismatches 23.01% 22.85% 22.19% 6.21% 20.56% 19.56%
Six pairwise genotype comparisons of four inbred mouse strains were performed at 542,190 SNPs distributed across the genome to assess the extent of
genetic relatedness.
*The fraction of the genome that was deﬁned as identical by descent (IBD) between any two strains was determined by calculating the percentage of those
two genomes with 98% or greater identity over windows of 100 SNPs.
yThe regions of the genome that were non-IBD between 129 S6 and 129 S1 contained 17,713 SNPs of the Mouse Diversity Array. Pairwise genotype comparisons
of the four inbred mouse strains were performed at these 17,713 SNPs to assess the genetic relatedness within the 129 S6 and 129 S1 non-IBD regions.
Anti-MPO Glomerulonephritis(PBL) and % donor CD45 positive PBL. Four weeks after
irradiation and transplantation, >95% of PBL were donor
derived. Anti-MPO was administrated intravenously 4
weeks after BM transfer, and 6 days later, NCGN was
assessed. Rag2/ B6 mice (n Z 4) transplanted with
129S6 BM developed 79% crescents (69% to 85%), which
is similar to Rag2/ 129S6 mice (Figure 4). Rag2/129S6
mice (n Z 6) that received BM from B6 mice had 17%
crescents (9% to 22%) similar to Rag2/ B6. Immuno-
histochemical staining for neutrophils and macrophages
demonstrated more neutrophils in glomeruli of B6 mice
with 129S6 BM compared to 129S6 mice with B6 BM,
although there was no difference in macrophages (Table 4).
Thus, genetically determined characteristics of BM-derived
cells are responsible for the marked differences in disease
between B6 and 129S6 mice, and this is associated with
glomerular neutrophil inﬁltration.
Genetically Determined Differences in Activation of
Neutrophils by Anti-MPO
Neutrophils were primed with TNF-a, incubated with anti-
MPO IgG, and superoxide generation was then measured.Figure 3 The 3.3% non-IBD fraction is conﬁned to 15 regions over 90.8
Mb on nine chromosomes. In the regions in which 129S1 and 129S6 are
genetically identical, the blue and red lines are close together, whereas in
divergent regions, they are farther apart.
The American Journal of Pathology - ajp.amjpathol.orgAnti-MPO IgG caused more activation of neutrophils from
129S6 compared to neutrophils from B6 or 129S1 mice
(Figure 5), which correlated with NCGN severity in these
strains (Table 1 and Figure 2), and demonstrated that genetic
differences inﬂuence neutrophil activation by anti-MPO.
Discussion
Differences in severity of NCGN induced by anti-MPO IgG
among mouse strains indicate that severity is genetically
determined and that there are either protective alleles in less
affected strains, or severity alleles in more severely affected
strains. Because 129S6  B6 F1 mice exhibit less severe
NCGN than 129S6, either some or all B6 alleles are
protective and have a dominant mode of inheritance, or
129S6 severity alleles are recessive. NCGN phenotypes in
129S6  B6 F2 mice span the extremes seen in 129S6 and
B6 strains, suggesting that NCGN induced by anti-MPO is
a polygenic trait.
Comparative genome analysis using the mouse diversity
array revealed differences in genomic architecture under-
lying differences in NCGN phenotypes among four inbredFigure 4 BM chimeric mice were created by transplanting (Tx) 129S6 or
B6 BM into lethally irradiated Rag2/ B6 or Rag2/ 129S6 mice,
respectively. The severity of glomerulonephritis induced by anti-MPO IgG
was determined in the BM chimeras and the corresponding nonchimeric
donor strains. The severity of crescent formation corresponded with the BM
genotype, not the somatic genotype.
1223
Table 4 Pathologic Features in Bone Marrow Chimeric Mice That
Received Anti-MPO IgG.
129S6 BM in
B6 body
B6 BM in
129S6 body
% Gloms with crescents 79.29  7.14% 17.00  4.77%
% Gloms with neutrophils 84.13  4.17% 21.5  8.95%
Neutrophils per glom 3.15  0.30 0.38  0.17
% Gloms with macrophages 6.25  1.89% 5.0  1.63%
Macrophages per glom 0.07  0.03 0.05  0.02
Neutrophils and macrophages were detected by immunohistochemistry.
Gloms, glomeruli.
Figure 5 In vitro activation by anti-MPO IgG of neutrophils. Neutro-
phils from B6 (black circles), 129S6 (black triangles), and 129S1 (black
squares) mice were primed with TNF-a, incubated with murine anti-MPO
IgG, and superoxide generation was measured as an indicator of neutro-
phil activation. Negative control experiments included neutrophils from B6
(white circles), 129S6 (white triangles), and 129S1 (white squares), all
treated with TNF-a, but no anti-MPO IgG.
Xiao et alstrains. This comparison demonstrated that genomes of 129
substrains do not contain uniformly distributed de novo
mutations acquired since the strains split; instead, their
genomes are highly divergent over discrete regions. Genes
responsible for difference in NCGN phenotype between the
129 substrains may be in the 90.8 Mb that differs between
these substrains. However, it is also possible that genetic
interactions between loci in IBD and non-IBD regions
inﬂuence disease severity. Linkage analysis planned for the
future in an F2 population between 129S6 and 129S1 mice
could address this possibility; moreover, linkage analysis of
an S6eS1 F2 intercross, or backcross, would simplify
genetic architecture within the mapping population and
increase the power to detect variants associated with NCGN
in the 15 candidate regions. De novo mutation could account
for differences between 129S1 and 129S6; however, de
novo mutation could not be assessed without 129S6
genomic sequence.
Several of these 761 known genes in the non-IBD frac-
tion of 129S1 and 129S6 (Supplemental Table S1) are
particularly interesting based on previous studies on the
pathogenesis of ANCA disease,1-7 including genes involved
in antibodyecell surface interaction, epigenetic gene regu-
lation, complement activation, Fc receptor engagement, and
cell signaling. Given the evidence for an important role for
FcgR in the pathogenesis of ANCA disease,41e47 it is
interesting that there are multiple Fc receptor genes in the
129S6/129S1 non-IBD regions: Fc gamma receptor 1 gene
(Fcgr1) in region 2 on Chromosome 3, and Fc receptor-like
5 (Fcrl5), Fc receptor-like 1 (Fcrl1), and Fc receptor-like
scavenger (Fcrls) in region 2 on Chromosome 3.
F2 intercross between B6 and 129S6 was used to inves-
tigate genetic factors affecting NCGN severity. The NCGN
phenotypes in 129S6  B6 F2 mice span the range seen in
129S6 and B6, suggesting that NCGN induced by anti-MPO
IgG is a polygenic trait. A signiﬁcant QTL was not detected,
suggesting complex genetic architecture, possibly involving
epistasis. However, multiple suggestive peaks were ob-
served, three of which spanned non-IBD regions between
the 129 substrains. Suggestive QTL peaks were observed
for log-transformed % crescents on Chromosomes 4, 5, 7, 9,
and 10; however, no QTL peaks reached sufﬁcient genome-
wide signiﬁcance, as calculated for 5% and 10% error
thresholds. The suggestive regions on Chromosome 5 and1224Chromosome 7 are the second and third largest genomic
regions of divergence, spanning 26 Mb. Two genes in-
volved in epigenetic histone modiﬁcations reside on Chro-
mosome 7: Eed, a component of the Polycomb repressive
complex 2 (PRC2) that methylates H3K27, and Mll4, an
H3K4 methyltransferase. Dysregulated expression of ANCA
autoantigen genes occurs in neutrophils of ANCA disease
patients,48e50 and is associated with disrupted epigenetic
silencing via histone methylation of autoantigen genes.50
This overlap between a non-IBD region, a suggestive QTL,
and a transcriptional regulatory mechanism for ANCA
autoantigen genes is intriguing and will be studied further.
The absence of a signiﬁcant QTL for NCGN severity in
our model differs from the identiﬁcation of QTL in other
rodent models of crescentic glomerulonephritis.51,52 An
important distinction is that these studies investigated disease
susceptibility, whereas our study investigated severity. More
importantly, both of these models have either a more com-
plex interplay of multiple pathogenic processes in addition to
ANCA-mediated injury51 or a different pathogenic process
that does not involve ANCA.52 The most relevant model to
ours is induced inWistar Kyoto (WKY) rats by immunization
with human MPO, which results in anti-MPO antibodies that
cross-react with rat MPO and cause NCGN.53 Unlike WKY
rats, Lewis, Wistar Furth, and Brown Norway rats immu-
nized with human MPO do not develop NCGN, even though
they develop comparable levels of anti-MPO to WKY rats.
We hypothesized that this strain difference was more likely
caused by genetically determined differences in the innate
immune response rather than a difference in the adaptive
immune response. This is in agreement with the ﬁndings in
our study that show that identical injections of anti-MPO IgG
into different mouse strains induce very different degrees of
NCGN, thus implicating difference in innate immunity rather
than adaptive immunity as the basis for the differences in
pathogenesis.ajp.amjpathol.org - The American Journal of Pathology
Anti-MPO GlomerulonephritisConclusion
The severity of anti-MPOeinduced NCGN in this mouse
model is genetically modulated, and this genetic inﬂuence
acts through modulation of responsivity of neutrophils to
activation by ANCA. Linkage analysis suggests that this is
a complex polygenic trait. Additional studies will be
required to identify the genes and regulatory mechanisms
responsible for this modulation. These genes and gene
products may have important roles in pathogenesis of
human ANCA disease, and could be markers of disease
activity and outcome, as well as targets for therapy.Acknowledgments
We thank Yichun Hu (UNC Kidney Center, Chapel Hill,
NC) for statistical analysis.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2012.12.006.References
1. Falk RJ, Jennette JC: ANCA disease: where is this ﬁeld going? J Am
Soc Nephrol 2010, 21:745e752
2. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N,
Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies
speciﬁc for myeloperoxidase cause glomerulonephritis and vasculitis
in mice. J Clin Invest 2002, 110:955e963
3. Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Falk RJ, Jennette JC: A
major role for neutrophils in anti-myeloperoxidase antibody induced
necrotizing and crescentic glomerulonephritis. Am J Pathol 2005, 167:
39e45
4. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC: Alternative
complement pathway in the pathogenesis of disease mediated by
antineutrophil cytoplasmic autoantibodies. Am J Pathol 2007, 170:
52e64
5. Jennette JC, Xiao H, Falk R, Gasim AM: Experimental models of
vasculitis and glomerulonephritis induced by antineutrophil cyto-
plasmic autoantibodies. Contrib Nephrol 2011, 169:211e220
6. Schreiber A, Xiao H, Falk RJ, Jennette JC: Bone marrow-derived cells
are sufﬁcient and necessary targets to mediate glomerulonephritis and
vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc
Nephrol 2006, 17:3355e3364
7. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R:
C5a receptor mediates neutrophil activation and ANCA-induced
glomerulonephritis. J Am Soc Nephrol 2009, 20:289e298
8. Jennette JC: Rapidly progressive and crescentic glomerulonephritis.
Kidney Int 2003, 63:1164e1172
9. Hay EM, Beaman M, Ralston AJ, Ackrill P, Bernstein RM, Holt PJ:
Wegener’s granulomatosis occurring in siblings. Br J Rheumatol 1991,
30:144e145
10. Muniain MA, Moreno JC, Gonzalez Campora R: Wegener’s gran-
ulomatosis in two sisters. Ann Rheum Dis 1986, 45:417e421
11. Nowack R, Lehmann H, Flores-Suarez LF, Nanhou A, van der
Woude FJ: Familial occurrence of systemic vasculitis and rapidly
progressive glomerulonephritis. Am J Kidney Dis 1999, 34:364e373The American Journal of Pathology - ajp.amjpathol.org12. Brener Z, Cohen L, Goldberg SJ, Kaufman AM: ANCA-associated
vasculitis in Greek siblings with chronic exposure to silica. Am J
Kidney Dis 2001, 38:E28
13. Manganelli P, Giacosa R, Fietta P, Zanetti A, Neri TM: Familial
vasculitides: churg-Strauss syndrome and Wegener’s granulomatosis
in 2 ﬁrst-degree relatives. J Rheumatol 2003, 30:618e621
14. Knight A, Sandin S, Askling J: Risks and relative risks of Wegener’s
granulomatosis among close relatives of patients with the disease.
Arthritis Rheum 2008, 58:302e307
15. O’Donnell JL, Stevanovic VR, Frampton C, Stamp LK, Chapman PT:
Wegener’s granulomatosis in New Zealand: evidence for a latitude
dependent incidence gradient. Intern Med J 2007, 37:242e246
16. Mahr A, Guillevin L, Poissonnet M, Ayme S: Prevalences of poly-
arteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis,
and Churg-Strauss syndrome in a French urban multiethnic population
in 2000: a capture-recapture estimate. Arthritis Rheum 2004, 51:
92e99
17. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC,
Nachman PH: Predictors of relapse and treatment resistance in anti-
neutrophil cytoplasmic antibody-associated small-vessel vasculitis.
Ann Intern Med 2005, 143:621e631
18. Spencer SJ, Burns A, Gaskin G, Pusey CD, Rees AJ: HLA class II
speciﬁcities in vasculitis with antibodies to neutrophil cytoplasmic
antigens. Kidney Int 1992, 41:1059e1063
19. Esnault VL, Testa A, Audrain M, Rogé C, Barrier JH, Sesboüé R,
Martin JP, Lesavre P: Alpha 1-antitrypsin genetic polymorphism in
ANCA positive systemic vasculitis. Kidney Int 1993, 43:1329e1332
20. Grifﬁth ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD:
C-antineutrophil cytoplasmic antibody positivity in vasculitis patients
is associated with the Z allele of alpha-1-antitrypsin, and P-anti-
neutrophil cytoplasmic antibody positivity with the S allele. Nephrol
Dial Transplant 1996, 11:438e443
21. Jagiello P, Gencik M, Arning L, Wieczorek S, Kunstmann E,
Csernok E, Gross WL, Epplen JT: New genomic region for Wegener’s
granulomatosis as revealed by an extended association screen with 202
apoptosis-related genes. Hum Genet 2004, 114:468e477
22. HeckmannM, Holle JU, Arning L, Knaup S, Hellmich B, Nothnagel M,
Jagiello P, Gross WL, Epplen JT, Wieczorek S: The Wegener’s gran-
ulomatosis quantitative trait locus on chromosome 6p21.3 as charac-
terised by tagSNP genotyping. Ann Rheum Dis 2008, 67:972e979
23. Carr EJ, Clatworthy MR, Lowe CE, Todd JA, Wong A, Vyse TJ,
Kamesh L, Watts RA, Lyons PA, Smith KG: Contrasting genetic
association of IL2RA with SLE and ANCA-associated vasculitis.
BMC Med Genet 2009, 10:22
24. Carr EJ, Niederer HA, Williams J, Harper L, Watts RA, Lyons PA,
Smith KG: Conﬁrmation of the genetic association of CTLA4 and
PTPN22 with ANCA-associated vasculitis. BMCMed Genet 2009, 10:
121
25. Kamesh L, Heward JM, Williams JM, Gough SC, Chavele KM,
Salama A, Pusey C, Savage CO, Harper L: CT60 and _49 poly-
morphisms of CTLA 4 are associated with ANCA-positive small
vessel vasculitis. Rheumatology (Oxford) 2009, 48:1502e1505
26. Stassen PM, Cohen-Tervaert JW, Lems SP, Hepkema BG,
Kallenberg CG, Stegeman CA: HLA-DR4. DR13(6) and the ancestral
haplotype A1B8DR3 are associated with ANCA-associated vasculitis
and Wegener’s granulomatosis. Rheumatology (Oxford) 2009, 48:
622e625
27. Willcocks LC, Lyons PA, Rees AJ, Smith KG: The contribution of
genetic variation and infection to the pathogenesis of ANCA associated
systemic vasculitis. Arthritis Res Ther 2010, 12:202
28. Cao Y, Schmitz JL, Yang J, Hogan SL, Bunch D, Hu Y, Jennette CE,
Berg EA, Arnett FC Jr, Jennette JC, Falk RJ, Preston GA: DRB1*15
allele is a risk factor for PR3-ANCA disease in African Americans.
J Am Soc Nephrol 2011, 122:1161e1167
29. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al:
Genetically distinct subsets within ANCA-associated vasculitis. N
Engl J Med 2012, 367:214e2231225
Xiao et al30. Aratani Y, Koyama H, Nyui S, Suzuki K, Kura F, Maeda N: Severe
impairment in early host defense against Candida albicans in mice
deﬁcient in myeloperoxidase. Infect Immun 1999, 67:1828e1836
31. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J,
et al: The Collaborative Cross, a community resource for the genetic
analysis of complex traits. Nat Genet 2004, 36:1133e1137
32. Aylor DL, Valdar W, Foulds-Mathes W, Buus RJ, Verdugo RA,
Baric RS, et al: Genetic analysis of complex traits in the emerging
Collaborative Cross. Genome Research 2011, 21:1213e1222
33. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT,
Festing MF, Fisher EM: Genealogies of mouse inbred strains. Nat
Genet 2000, 24:23e25
34. Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE,
Sharp JJ: Genetic variation among 129 substrains and its importance
for targeted mutagenesis in mice. Nat Genet 1997, 16:19e27
35. Threadgill DW, Yee D, Matin A, Nadeau JH, Magnuson T: Genealogy
of the 129 inbred strains: 129/SvJ is a contaminated inbred strain.
Mamm Genome 1997, 8:390e393
36. Yang H, Ding Y, Hutchins LN, Szatkiewicz J, Bell TA, Paigen BJ,
Graber JH, de Villena FP, Churchill GA: A customized and versatile
high-density genotyping array for the mouse. Nat Methods 2009, 6:
663e666
37. Broman KW, Wu H, Sen S, Churchill GA: QTL mapping in experi-
mental crosses. Bioinformatics 2003, 19:889e890
38. Sen S, Johannes F, Broman KW: Selective genotyping and pheno-
typing strategies in a complex trait context. Genetics 2009, 181:
1613e1626
39. Churchill GA, Doerge RW: Empirical threshold values for quantitative
trait mapping. Genetics 1994, 138:963e971
40. Yang H, Wang JR, Didion JP, Buus RJ, Bell TA, Welsh CE,
Bonhomme F, Yu AH, Nachman MW, Pialek J, Tucker P, Boursot P,
McMillan L, Churchill GA, de Villena FP: Subspeciﬁc origin and
haplotype diversity in the laboratorymouse.NatGenet 2011, 43:648e655
41. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL,
Kimberly RP: Anti-neutrophil cytoplasmic antibodies engage and
activate human neutrophils via Fc gamma RIIa. J Immunol 1994, 153:
1271e1280
42. Mulder AH, Heeringa P, Brouwer E, Limburg PC, Kallenberg CG:
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies
(ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol
1994, 98:270e278
43. Reumaux D, Vossebeld PJ, Roos D, Verhoeven AJ: Effect of tumor
necrosis factor-induced integrin activation on Fc gamma receptor II-
mediated signal transduction: relevance for activation of neutrophils
by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 1995,
86:3189e3195122644. Nolan SL, Kalia N, Nash GB, Kamel D, Heeringa P, Savage CO:
Mechanisms of ANCA-mediated leukocyte-endothelial cell interac-
tions in vivo. J Am Soc Nephrol 2008, 19:973e984
45. Kelley JM, Monach PA, Ji C, Zhou Y, Wu J, Tanaka S, Mahr AD,
Johnson S, McAlear C, Cuthbertson D, Carette S, Davis JC Jr,
Dellaripa PF, Hoffman GS, Khalidi N, Langford CA, Seo P, St
Clair EW, Specks U, Stone JH, Spiera RF, Ytterberg SR, Merkel PA,
Edberg JC, Kimberly RP: IgA and IgG antineutrophil cytoplasmic
antibody engagement of Fc receptor genetic variants inﬂuences gran-
ulomatosis with polyangiitis. Proc Natl Acad Sci U S A 2011, 108:
20736e20741
46. Edberg JC, Wainstein E, Wu J, Csernok E, Sneller MC, Hoffman GS,
Keystone EC, Gross WL, Kimberly RP: Analysis of Fc gamma RII
gene polymorphisms in Wegener’s granulomatosis. Exp Clin Immu-
nogenet 1997, 14:183e195
47. Nester C, Lionaki S, Hyunsook C, Edberg J, Kimberly R,
Wilhelmsen K, Jennette JC, Falk R: Polymorphisms aassociated with
the pulmonary phenotype of antineutrophil cytoplasmic autoantibody
vasculitis [Abstract]. J Am Soc Nephrol 2007, 18:784A
48. Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL,
Thomas R, Sullivan P, Jennette JC, Falk RJ, Preston G: Circumvention
of normal constraints on granule protein gene expression in peripheral
blood neutrophils and monocytes of patients with antineutrophil
cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc
Nephrol 2000, 15:2103e2114
49. Ohlsson S, Hellmark T, Pieters K, Sturfelt G, Wieslander J,
Segelmark M: Increased monocyte transcription of the proteinase 3
gene in small vessel vasculitis. Clin Exp Immunol 2005, 141:174e182
50. Ciavatta DJ, Yang J, Preston GA, Badhwar AK, Xiao H, Hewins P,
Nester CM, Pendergraft WF 3rd, Magnuson T, Jennette JC, Falk RJ:
Epigenetic basis for aberrant upregulation of autoantigen genes in
humans with ANCA vasculitis. J Clin Invest 2010, 120:3209e3219
51. HamanoY,TsukamotoK,AbeM,SunGD,ZhangD, FujiiH,Matsuoka S,
Tanaka M, Ishida-Okawara A, Tachikawa H, Nishimura H, Tokunaka K,
Hirose S, Suzuki K: Genetic dissection of vasculitis, myeloperoxidase-
speciﬁc antineutrophil cytoplasmic autoantibody production, and related
traits in spontaneous crescentic glomerulonephritis-forming/Kinjohmice. J
Immunol 2006, 176:3662e3673
52. Reynolds J, Cook PR, Behmoaras J, Smith J, Bhangal G, Tadros S,
Tee J, Salama AD, Evans DJ, Aitman TJ, Cook HT, Pusey CD:
Genetic susceptibility to experimental autoimmune glomerulonephritis
in the Wistar Kyoto rat. Am J Pathol 2012, 180:1843e1851
53. Little MA, Smyth L, Salama AD, Mukherjee S, Smith J, Haskard D,
Nourshargh S, Cook HT, Pusey CD: Experimental autoimmune vascu-
litis: an animal model of anti-neutrophil cytoplasmic autoantibody-
associated systemic vasculitis. Am J Pathol 2009, 174:1212e1220ajp.amjpathol.org - The American Journal of Pathology
